| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94b51d317764e2f4f1bbcb355b274c8b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D231-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-416
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4162 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D231-56 |
| filingDate |
2013-01-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a5e8550cb6579bb22f03a04ea686ec3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a811f08d4e20eb0dcc0f0278eb9253d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eef263e9041d78d27352f96c2cfd1e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeada2359e8faa731eb9f7dc1580c6a7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_31fd13ddc5bd50e6ee15e2685a562509 |
| publicationDate |
2013-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013123296-A1 |
| titleOfInvention |
Lonidamine analogues for fertility management |
| abstract |
Fertility management can include: administering to the subject one or more doses of a compound according to Formula I so as to reduce fertility in the subject. Fertility management can also include administering an effective amount of the compound to: impair Sertoli cell function in a male subject; inhibit spermatogenesis in the subject; reduce testis weight in the subject; reduce ovary weight in a female subject; reduce serum progesterone in the female subject; impair ovarian follicle function in the female subject; causing reversible fertility in the subject. In order to return fertility, the method can include ceasing administration of the compound to the subject so as to return fertility in the subject. The compound can be administered for irreversibly sterilizing the subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9512119-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9650380-B2 |
| priorityDate |
2004-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |